OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Nelson on the Benefit of Primary Tumor Resection in mCRC

March 11th 2020

Douglas A. Nelson, MD, associate professor in the Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the benefit of primary tumor resection in patients with metastatic colorectal cancer (mCRC).

Dr. Tolaney on Navigating Adjuvant Therapy in Early-Stage HER2+ Breast Cancer

March 11th 2020

Sara M. Tolaney, MD, MPH, associate director, Susan F. Smith’s Center for Women’s Cancers, director, Clinical Trials, Breast Oncology, senior physician, Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses considerations for adjuvant therapy in patients with early-stage HER2-positive breast cancer.

Dr. Coleman on the VELIA Trial Impact on Ovarian Cancer Practice

March 11th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the impact of the VELIA trial on ovarian cancer practice.

Dr. Musher on Current Therapies for HCC

March 11th 2020

Benjamin Leon Musher, MD, discusses the current treatment options for patients with hepatocellular carcinoma.

Dr. Overman on Investigational Targeted Therapies in mCRC

March 11th 2020

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses investigational targeted therapies in metastatic colorectal cancer (mCRC).

Dr. Abdul-Hay on the Use of BiTEs in ALL

March 11th 2020

Mohammad Maher Abdul-Hay, MD, an assistant professor in the Department of Medicine; director of the Clinical Leukemia Program in NYU Langone Health’s Perlmutter Cancer Center; and associate director for research in the Bellevue Cancer Center, discusses the use of bispecific T-cell engagers (BiTEs) in acute lymphoblastic leukemia (ALL).

Dr. Dimou on Limitations of TMB as a Biomarker in Lung Cancer

March 11th 2020

Anastasios (Tassos) Dimou, MD, discusses the limitations of tumor mutational burden as a biomarker in lung cancer.

Dr. Rugo on the Utility of Margetuximab in HER2+ Metastatic Breast Cancer

March 11th 2020

Hope S. Rugo, MD, discusses the utility of margetuximab in HER2-positive metastatic breast cancer.

Dr. Villa on Retrospective Data of Bendamustine/Rituximab in MCL

March 10th 2020

Diego Villa, MD, MPH, discusses the findings of a retrospective analysis looking at bendamustine plus rituximab in mantle cell lymphoma.

Dr. Hellmann on the Impact of Systemic Therapy on Surgery in Ovarian Cancer

March 10th 2020

Mira Hellmann, MD, discusses the impact of surgery on patients with ovarian cancer.

Dr. Tsao on Rationale for Staging Renal Cell Carcinoma

March 10th 2020

Che-Kai Tsao, MD, discusses the rationale behind staging disease, especially in the context of when patients are diagnosed with renal cell carcinoma.

Dr. Polsky on the Unmet Need of Clinical Utility in Liquid Biopsy

March 10th 2020

David Polsky, MD, PhD, discusses the unmet need of clinical utility in liquid biopsy.

Dr. Patel on the Unmet Need of FLT3 Inhibitors in AML Treatment

March 10th 2020

Prapti Patel, MD, discusses the unmet need of FLT3 inhibitors in the treatment of patients with acute myeloid leukemia.

Dr. Freedland on the Importance of Conducting Real-World Analyses in Prostate Cancer

March 10th 2020

Stephen J. Freedland, MD, discusses the importance of conducting real-world analyses in prostate cancer.

Dr. Pant on Immunotherapy Combos and Upcoming Developments in Pancreatic Cancer

March 10th 2020

Shubham Pant, MD, discusses combination immunotherapies and upcoming developments in pancreatic cancer.

Dr. Raphael on the CLARITY Trial in CLL

March 10th 2020

Bruce G. Raphael, MD, a clinical professor in the Department of Medicine at NYU Langone Health, discusses the phase II CLARITY trial in chronic lymphocytic leukemia (CLL).

Dr. Garcia on the Managing Thrombocytopenia With Navitoclax in Myelofibrosis

March 10th 2020

Jacqueline S. Garcia, MD, instructor in medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the management of thrombocytopenia with navitoclax in patients with myelofibrosis.

Dr. O'Malley on the Optimal Use of PARP Inhibitors in Advanced Ovarian Cancer

March 10th 2020

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, and director, Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the optimal use of PARP inhibitors as frontline maintenance therapy in patients with advanced ovarian cancer.

The Applications of a Mixed Reality Laboratory

March 7th 2020

Andrea Sboner, MS, PhD, assistant professor of computational genomics in computational biomedicine and of pathology and laboratory medicine, Weill Cornell Medicine, discusses the applications of a mixed reality laboratory.

Dr. Ledermann on Response to Rucaparib in Recurrent Ovarian Cancer

March 7th 2020

Jonathan A. Ledermann, BSc, MD, FRCP, professor of medical oncology, UCL Cancer Institute, University College London, and an honorary consultant medical oncologist, UCL Hospitals, discusses responses to rucaparib (Rubraca) maintenance in ovarian cancer.